Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Boehringer Ingelheim
Harvard Business School
Medtronic
AstraZeneca

Last Updated: October 1, 2022

SOLIRIS Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Recent Clinical Trials for SOLIRIS

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Regeneron PharmaceuticalsPhase 3
BioCryst PharmaceuticalsPhase 2
Hansa Biopharma ABPhase 3

See all SOLIRIS clinical trials

Recent Litigation for SOLIRIS

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Alvotech hf.2021-05-28
Alvotech USA Inc. v. Abbvie Inc2021-05-11
AbbVie Inc. v. Alvotech hf.2021-04-27

See all SOLIRIS litigation

PTAB Litigation
PetitionerDate
Amgen Inc.2019-02-28
Amgen, Inc.2019-02-28
2017-12-20

See all SOLIRIS litigation

Pharmacology for SOLIRIS
Mechanism of ActionComplement Inhibitors
Established Pharmacologic ClassComplement Inhibitor
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SOLIRIS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SOLIRIS Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 See Plans and Pricing 2019-03-12 Company disclosures
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 See Plans and Pricing 2027-03-15 Company disclosures
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 See Plans and Pricing 2027-03-15 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for SOLIRIS Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for SOLIRIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC002/2010 Ireland See Plans and Pricing SPC002/2010: 20100902, EXPIRES: 20200430
SZ 12/2010 Austria See Plans and Pricing PRODUCT NAME: ECULIZUMAB
2010C/010 Belgium See Plans and Pricing PRODUCT NAME: ECULIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/07/393/001 20070620
12/2010 Austria See Plans and Pricing PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
C300433 Netherlands See Plans and Pricing PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
132010901820871 Italy See Plans and Pricing PRODUCT NAME: ECULIZUMAB(SOLIRIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/07/393/001, 20070620
CA 2010 00003 Denmark See Plans and Pricing
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Boehringer Ingelheim
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.